These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22416093)

  • 1. Clopidogrel dosing based on genotype.
    Alexopoulos D; Xanthopoulou I
    JAMA; 2012 Mar; 307(10):1024; author reply 1024-5. PubMed ID: 22416093
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS
    JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

  • 4. Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy.
    Chyrchel B; Surdacki A; Chyrchel M; Dudek D; Dubiel JS
    Int J Cardiol; 2011 May; 149(1):124-5. PubMed ID: 21345502
    [No Abstract]   [Full Text] [Related]  

  • 5. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical-scientific notes.
    Dick RJ; Byron KA; Dear AE
    Intern Med J; 2012 Oct; 42 Suppl 5():7-8. PubMed ID: 23035675
    [No Abstract]   [Full Text] [Related]  

  • 7. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 8. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel hyporesponsiveness: are we all the same?
    Tan DS
    Am J Health Syst Pharm; 2011 Sep; 68(17):1578-80; author reply 1580. PubMed ID: 21856801
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.
    Snoep JD
    Circ Cardiovasc Interv; 2011 Oct; 4(5):401-4. PubMed ID: 22010185
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenomics and clopidogrel: irrational exuberance?
    Nissen SE
    JAMA; 2011 Dec; 306(24):2727-8. PubMed ID: 22203545
    [No Abstract]   [Full Text] [Related]  

  • 13. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we override clopidogrel resistance?
    Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
    Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
    Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
    [No Abstract]   [Full Text] [Related]  

  • 16. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
    Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genotype and cardiovascular events.
    Siasos G; Tousoulis D; Stefanadis C
    JAMA; 2012 Apr; 307(14):1483-4; author reply 1484-5. PubMed ID: 22496257
    [No Abstract]   [Full Text] [Related]  

  • 18. CYP2C19 genotype and cardiovascular events.
    Mega JL; Topol EJ; Sabatine MS
    JAMA; 2012 Apr; 307(14):1482-3; author reply 1484-5. PubMed ID: 22496256
    [No Abstract]   [Full Text] [Related]  

  • 19. CYP2C19 genotype and cardiovascular events.
    Shuldiner AR; Vesely MR; Fisch A
    JAMA; 2012 Apr; 307(14):1482; author reply 1484-5. PubMed ID: 22496255
    [No Abstract]   [Full Text] [Related]  

  • 20. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.